MTOR and urinary bladder carcinoma: Mounting evidences proposed that the PI3K/AKT/mTOR pathways are generally activated in many cancers including bladder cancer, and inhibitors of these core genes are displaying great promise as the latent anticancer agents (Bellacosa et al., 2005[4]; Bartholomeusz and Gonzalez-Angulo, 2012[3]).